Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression.

Tomoko Mizuno, Naoko Inoshita, Noriaki Fukuhara, Keita Tatsushima, Akira Takeshita, Shozo Yamada, Hiroshi Nishioka, Yasuhiro Takeuchi

Internal medicine (Tokyo, Japan) 2022 Mar 01

filter terms:

Pasireotide, which has a high affinity for somatostatin receptor (SSTR) 5, has attracted attention as a new treatment for refractory Cushing's disease. The patient was a 28-year-old man. He had refractory Cushing's disease and underwent multiple surgeries, radiotherapy, and medication therapy. An examination of the adenoma by immunohistochemistry revealed a low SSTR5 expression. An USP8 mutation was not detected by reverse transcription polymerase chain reaction. Although we administered pasireotide, it was ineffective. While a further investigation is necessary, the analysis of SSTR5 expression may support the prediction of the efficiency of pasireotide for Cushing's disease. We report this case as a useful reference when considering whether or not to use pasireotide for refractory corticotroph adenomas.

Citation

Tomoko Mizuno, Naoko Inoshita, Noriaki Fukuhara, Keita Tatsushima, Akira Takeshita, Shozo Yamada, Hiroshi Nishioka, Yasuhiro Takeuchi. Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression. Internal medicine (Tokyo, Japan). 2022 Mar 01;61(5):679-685